Forbion Growth Management B.V.
CIK 0001918318 Name as filed on the most recent filing
Filed as Forbion Growth Management B.V. (11)
39 transaction lines · from 11 filings · filed 2024-10-18 to 2025-01-02 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2024-12-30 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 29,846 disposed | 25.54 | 762,174.32 | Form 4, filing 0000950170-25-000445 | |
| 2024-12-27 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 41,472 disposed | 25.95 | 1,076,289.64 | Form 4, filing 0000950170-24-141146 | |
| 2024-12-26 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 33,438 disposed | 26.01 | 869,628.75 | Form 4, filing 0000950170-24-141146 | |
| 2024-12-24 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 16,164 disposed | 25.66 | 414,831.28 | Form 4, filing 0000950170-24-140408 | |
| 2024-12-23 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 25,132 disposed | 25.49 | 640,624.73 | Form 4, filing 0000950170-24-140408 | |
| 2024-12-20 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 44,143 disposed | 25.53 | 1,126,992.86 | Form 4, filing 0000950170-24-140408 | |
| 2024-12-20 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 5,629 disposed | 26.13 | 147,071.13 | Form 4, filing 0000950170-24-140408 | |
| 2024-12-19 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 56,506 disposed | 25.45 | 1,437,806.47 | Form 4, filing 0000950170-24-139069 | |
| 2024-12-18 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 54,518 disposed | 25.72 | 1,402,050.31 | Form 4, filing 0000950170-24-139069 | |
| 2024-12-18 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 46,210 disposed | 26.55 | 1,226,857.02 | Form 4, filing 0000950170-24-139069 | |
| 2024-12-17 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 66,648 disposed | 25.60 | 1,706,315.43 | Form 4, filing 0000950170-24-137893 | |
| 2024-12-17 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 47,736 disposed | 26.45 | 1,262,440.58 | Form 4, filing 0000950170-24-137893 | |
| 2024-12-16 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 1,096 disposed | 25.00 | 27,400.00 | Form 4, filing 0000950170-24-137893 | |
| 2024-12-13 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 25,751 disposed | 25.01 | 644,047.96 | Form 4, filing 0000950170-24-136642 | |
| 2024-12-12 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 140,048 disposed | 25.25 | 3,536,212.00 | Form 4, filing 0000950170-24-136642 | |
| 2024-12-12 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 25,963 disposed | 26.18 | 679,615.28 | Form 4, filing 0000950170-24-136642 | |
| 2024-12-11 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 130,561 disposed | 25.26 | 3,298,453.94 | Form 4, filing 0000950170-24-135796 | |
| 2024-12-11 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 18,583 disposed | 26.40 | 490,684.12 | Form 4, filing 0000950170-24-135796 | |
| 2024-12-11 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 4,894 disposed | 27.11 | 132,671.45 | Form 4, filing 0000950170-24-135796 | |
| 2024-12-10 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 259,739 disposed | 25.22 | 6,550,202.00 | Form 4, filing 0000950170-24-135796 | |
| 2024-12-10 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 48,511 disposed | 26.15 | 1,268,606.31 | Form 4, filing 0000950170-24-135796 | |
| 2024-11-18 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 33,273 disposed | 25.08 | 834,440.26 | Form 4, filing 0000950170-24-128607 | |
| 2024-11-15 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 8,530 disposed | 25.02 | 213,435.95 | Form 4, filing 0000950170-24-128607 | |
| 2024-11-14 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 9,832 disposed | 25.01 | 245,856.04 | Form 4, filing 0000950170-24-127643 | |
| 2024-11-13 |
NewAmsterdam Pharma Co N.V. NAMS |
S, Open-market sale | 1,066 disposed | 25.00 | 26,654.58 | Form 4, filing 0000950170-24-127643 | |
| 2024-10-30 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 561,797 acquired | 8.90 | 4,999,993.30 | Form 4, filing 0000950170-24-120079 | |
| 2024-10-08 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 800 acquired | 6.60 | 5,278.48 | Form 4, filing 0000950170-24-115607 | |
| 2024-10-07 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 11,844 acquired | 6.55 | 77,530.82 | Form 4, filing 0000950170-24-115607 | |
| 2024-10-04 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 5,997 acquired | 6.54 | 39,241.97 | Form 4, filing 0000950170-24-115607 | |
| 2024-10-03 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 5,769 acquired | 6.48 | 37,396.97 | Form 4, filing 0000950170-24-115607 | |
| 2024-10-02 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 10,153 acquired | 6.37 | 64,696.95 | Form 4, filing 0000950170-24-115607 | |
| 2024-10-01 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 35,279 acquired | 6.44 | 227,157.95 | Form 4, filing 0000950170-24-115607 | |
| 2024-09-30 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 341,332 acquired | 6.34 | 2,163,362.22 | Form 4, filing 0000950170-24-115607 | |
| 2024-09-27 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 38,396 acquired | 5.94 | 228,010.81 | Form 4, filing 0000950170-24-115607 | |
| 2024-09-27 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 3,243 acquired | 6.38 | 20,688.39 | Form 4, filing 0000950170-24-115607 | |
| 2023-12-29 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 9,620 acquired | 9.09 | 87,450.61 | Form 4, filing 0000950170-24-115607 | |
| 2023-12-29 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 400 acquired | 8.30 | 3,320.00 | Form 4, filing 0000950170-24-115607 | |
| 2023-12-28 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 5,050 acquired | 7.69 | 38,826.92 | Form 4, filing 0000950170-24-115607 | |
| 2023-12-27 |
enGene Holdings Inc. ENGN |
P, Open-market purchase | 2,750 acquired | 7.17 | 19,711.45 | Form 4, filing 0000950170-24-115607 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Forbion Growth Management B.V., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001918318
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6